Cardiopulmonary effects of sufentanil long acting on sevoflurane anaesthesia in dogs.
OBJECTIVE
To evaluate the cardiopulmonary effects of sufentanil long acting (SLA) in sevoflurane-anaesthetized dogs.


METHODS
Randomized prospective study. Animals Forty female dogs (beagles) aged 1-2 years, weighing 11.97 +/- 1.40 kg.


METHODS
The dogs were divided into five groups of eight. Two control groups were used: group A received intramuscular (IM), SLA (50 microg kg(-1)) alone, while group B received the SLA vehicle followed by sevoflurane anaesthesia for 90 minutes. In the other groups, SLA (50 microg kg(-1) IM) was given immediately before (group C(0)), 15 minutes before (group D(15)) or 30 minutes (group E(30)) before induction [with intravenous (IV) thiopental] of sevoflurane anaesthesia lasting for 90 minutes. Heart rate, arterial blood pressure, respiratory rate (f(r)), arterial oxygen haemoglobin saturation and end-tidal sevoflurane concentration (Fe'SEVO) were measured every 10 minutes during anaesthesia and at 2, 4 and 24 hours after induction (not Fe'SEVO). Acid-base and blood gas analyses were performed.


RESULTS
Sufentanil LA reduced heart rate and increased arterial CO(2) tensions during anaesthesia. Respiratory depression was least in group E(30) compared with groups C(0) and D(15). Bradycardia was present for at least 24 hours. Respiratory rate was least in group B although arterial O(2) and CO(2) tension values were acceptable up to 24 hours after anaesthesia.


CONCLUSIONS
Pre-anaesthetic medication with SLA moderately aggravated the cardiopulmonary effects of sevoflurane.


CONCLUSIONS
In spite of a moderate depressant effect on cardiorespiratory parameters, SLA may be of use as pre-anaesthetic medication before sevoflurane anaesthesia in dogs. Intermittent positive pressure ventilation may occasionally be necessary.
Department of Small Animal Medicine and Clinical Biology, Faculty of Veterinary Medicine, University of Ghent, Ghent, Belgium. ingeborgh.polis@UGent.be
Ingeborgh
I
Polis
Yves
Y
Moens
Dagmar
D
Hoeben
Mulenda
M
Tshamala
Yves
Y
Hoybergs
Frank
F
Gasthuys
D000759:Adjuvants, Anesthesia / Q000494:pharmacology*; D000758:Anesthesia / Q000662:veterinary*; D018685:Anesthetics, Inhalation / Q000494:pharmacology*; D000818:Animals; D003692:Delayed-Action Preparations; D004285:Dogs; D004347:Drug Interactions; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D008738:Methyl Ethers / Q000494:pharmacology*; D011292:Premedication; D012119:Respiration / Q000187:drug effects; D000077149:Sevoflurane; D017409:Sufentanil / Q000008:administration & dosage* / Q000494:pharmacology*
D000759:Adjuvants, Anesthesia; D018685:Anesthetics, Inhalation; D003692:Delayed-Action Preparations; D008738:Methyl Ethers; D000077149:Sevoflurane; D017409:Sufentanil